- VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
- VIVUS Reports 2016 Third Quarter Financial Results
- VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference
- VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
- VIVUS Extends Return Date of STENDRA Commercial Rights
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.